| This week's sponsor is Deloitte. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, June 27, 2018 Teva’s mega-cost-cutting drive hasn’t been popular with workers or its home country of Israel. Analysts, on the other hand, like what they’ve seen so far from the company’s new C-suite team. |
|
|
Top Stories Of The Week Tuesday, June 26, 2018 Roivant has laid off some staff and reassigned others to subsidiaries in a notable strategic shift. The changes see Roivant shed around 10% of its staff and cede responsibility for others to the heads of its portfolio of startups. Monday, June 25, 2018 The executive pyramid at Johnson & Johnson is going through a significant remake with pharma head Joaquin Duato taking on the consumer responsibilities held by Group Worldwide Chairman Sandra Peterson as she prepares to retire. Wednesday, June 27, 2018 Women only hold a quarter of all C-level biopharma jobs, and when they do make it to the top, women are overall paid far less compared to many of their male counterparts. Here, we list the top 5 highest-paid female biopharma executives based on their 2017 compensation. Monday, June 25, 2018 The FDA could become much smaller if a proposal by President Trump to separate the regulation of food and medicines comes into effect. Wednesday, June 27, 2018 AstraZeneca and Merck & Co. are looking at a $1 billion opportunity for Lynparza, thanks to new data that support using it to fight advanced ovarian cancer in certain women who have just been diagnosed, rather than after chemotherapy. It's the first PARP inhibitor to deliver a success in untreated women, adding to a string of firsts in its class. Wednesday, June 27, 2018 Sanofi, Verily and Sensile Medical are teaming up to develop an “all-in-one” insulin patch pump, primarily aimed at patients with Type 2 diabetes. Thursday, June 28, 2018 The team behind a much-hyped cancer-killing virus reports an "encouraging" 21% long-term survival rate in glioblastoma patients. But the number of patients who survived may be too small to know for sure if the treatment works. Tuesday, June 26, 2018 PPD unveiled a new patient enrollment model, dubbed PatientAdvantage, which uses big data to identify eligible patients and then connect them with possible study sites, inverting the traditional steps of clinical trial delivery. Tuesday, June 26, 2018 Indian biosimilar maker Biocon has had the taint of an FDA manufacturing citation erased with an agency action that indicates a key plant in Bangalore, India, is now in compliance. The regulatory overhang had delayed Biocon and partner Mylan getting some products approved. Wednesday, June 27, 2018 A new FDA study looking at millions of CMS hospitalization data points found that flu vaccines made from the newer, cell-based technology weren’t performing much better than traditional egg-based ones in seniors, a historically tough group to protect. | This week's sponsor is Systech. | | | [Webinar] Navigating the Path to Compliance: Two Pharmas Discuss Their Challenges and Successes
July 12, 2018 | 11am ET / 8am PT
You know you need to serialize to comply with government mandates such as DSCSA or EU FMD. But the journey from initially Googling "traceability" to achieving full serialization compliance is complex. Let us guide you through the challenges and outcomes with two pharmaceutical companies who have successfully navigated the path to compliance for their different businesses. Register Now. |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
